Inflammation due to ocular surface homeostasis imbalance caused by pterygia: tear lymphotoxin-alpha study and a literature review.
Dry eyes
Lymphotoxin-alpha
Ocular surface homeostasis
Pterygium
Tear film instability
Journal
Journal of ophthalmic inflammation and infection
ISSN: 1869-5760
Titre abrégé: J Ophthalmic Inflamm Infect
Pays: Germany
ID NLM: 101553216
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
10
03
2024
accepted:
10
06
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
To estimate the pterygium ocular surface state, and compare with healthy eyes and dry eyes. To investigate the inflammation due to pterygia growth by tear Lymphotoxin-alpha (LT α) test. Prospective, single-center study. 400 patients, divided into 100 pterygium group, 100 mild dry eye group, 100 moderate dry eye group, and 100 age-and sex-matched normal controls. The non-invasive break-up time (NIBUT), tear meniscus height (TMH) test, corneal fluorescein staining (CFS), meibomian gland loss score (MGs), and lipid layer thickness (LLT) were evaluated in all patients. Pterygium status and ocular status in the pterygium group were collected. The tear LT α test was conducted in the pterygium patients group. Pterygium can affect the ocular surface, leading to decreased tear film stability. The TMH, NIBUT, CFS, MGs, and lipid layer thickness can provide insights into this phenomenon. The presence of pterygium can change the structure and condition of the ocular surface. Tear LT α testing shows an abnormal decrease in LT α levels in pterygium patients. This indicates an immune-inflammation microenvironment that causes tissue repair deficiency. The dry eye triggered by the growth of pterygium may originate from the tear film instability due to pterygia. As an inflammatory index, LT α in the development of pterygium and the aggravation of dry eye patients can indicate that the ocular surface is in different inflammatory states. Future tear testing in LT α may be a potential indicator to assess the inflammatory status of the dry eye.
Identifiants
pubmed: 38874736
doi: 10.1186/s12348-024-00413-1
pii: 10.1186/s12348-024-00413-1
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Subventions
Organisme : Xiamen Municipal Guiding Project of Combination of Engineering with Medicine
ID : 3502Z20214ZD2195
Organisme : Xiamen Municipal Guiding Project of Combination of Engineering with Medicine
ID : 3502Z20214ZD2194
Organisme : Xiamen Municipal Guiding Project of Combination of Engineering with Medicine
ID : 3502Z20214ZD2196
Organisme : Xiamen Municipal Guiding Project of Medical and Health
ID : 3502Z20214ZD1209, 3502Z20224D1204
Informations de copyright
© 2024. The Author(s).
Références
Rezvan F et al (2018) Prevalence and risk factors of pterygium: a systematic review and meta-analysis. Surv Ophthalmol 63(5):719–735
doi: 10.1016/j.survophthal.2018.03.001
pubmed: 29551597
Wu H et al (2017) Meibomian gland dysfunction correlates to the tear Film instability and ocular discomfort in patients with Pterygium. Sci Rep 7:45115
doi: 10.1038/srep45115
pubmed: 28338041
pmcid: 5364464
Ye F et al (2017) Evaluation of meibomian gland and tear film changes in patients with pterygium. Indian J Ophthalmol 65(3):233–237
doi: 10.4103/ijo.IJO_743_16
pubmed: 28440253
pmcid: 5426129
Li N et al (2019) Tear Film Instability and Meibomian Gland Dysfunction correlate with the Pterygium size and thickness pre- and postexcision in patients with Pterygium. J Ophthalmol 2019:p5935239
doi: 10.1155/2019/5935239
Lucas B et al (2016) Lymphotoxin β receptor controls T cell progenitor entry to the Thymus. J Immunol 197(7):2665–2672
doi: 10.4049/jimmunol.1601189
pubmed: 27549174
pmcid: 5026032
Borelli A, Irla M (2021) Lymphotoxin: from the physiology to the regeneration of the thymic function. Cell Death Differ 28(8):2305–2314
doi: 10.1038/s41418-021-00834-8
pubmed: 34290396
pmcid: 8329281
Bauer J et al (2012) Lymphotoxin, NF-ĸB, and cancer: the dark side of cytokines. Dig Dis 30(5):453–468
doi: 10.1159/000341690
pubmed: 23108301
Paik B, Tong L (2023) Polymorphisms in Lymphotoxin-Alpha as the Missing Link in Prognosticating favourable response to Omega-3 supplementation for Dry Eye Disease: a narrative review. Int J Mol Sci, 24(4)
Hirose T et al (2018) The role of lymphotoxin-α in rheumatoid arthritis. Inflamm Res 67(6):495–501
doi: 10.1007/s00011-018-1139-6
pubmed: 29541795
Veiga-Parga T et al (2013) Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated inflammatory pathways. Microbes Infect 15(10–11):677–687
doi: 10.1016/j.micinf.2013.07.001
pubmed: 23850656
pmcid: 3769451
The definition and classification of dry eye disease: report of the definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf, (2007) 5(2): p. 75–92
Arita R et al (2008) Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology 115(5):911–915
doi: 10.1016/j.ophtha.2007.06.031
pubmed: 18452765
Arita R et al (2016) Tear interferometric patterns reflect clinical tear dynamics in Dry Eye patients. Invest Ophthalmol Vis Sci 57(8):3928–3934
doi: 10.1167/iovs.16-19788
pubmed: 27472080
Whitcher JP et al (2010) A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren’s Syndrome International Registry. Am J Ophthalmol 149(3):405–415
doi: 10.1016/j.ajo.2009.09.013
pubmed: 20035924
Vanathi M et al (2018) Corneal tomography and biomechanics in primary pterygium. Int Ophthalmol 38(2):663–671
doi: 10.1007/s10792-017-0514-6
pubmed: 28501948
Kadayifçilar SC, Orhan M, Irkeç M (1998) Tear functions in patients with pterygium. Acta Ophthalmol Scand 76(2):176–179
doi: 10.1034/j.1600-0420.1998.760210.x
pubmed: 9591948
Van Acker SI et al (2021) Pterygium-the Good, the bad, and the Ugly. Cells, 10(7)
Shahraki T, Arabi A, Feizi S (2021) Pterygium: an update on pathophysiology, clinical features, and management. Ther Adv Ophthalmol 13:25158414211020152
pubmed: 34104871
pmcid: 8170279
Safarzadeh M et al (2019) Comparative Assessment of tear function tests, tear Osmolarity, and Conjunctival Impression Cytology between patients with Pterygium and Healthy Eyes. J Ophthalmic Vis Res 14(1):11–17
doi: 10.4103/jovr.jovr_260_17
pubmed: 30820281
pmcid: 6388519
Ishioka M et al (2001) Pterygium and dry eye. Ophthalmologica 215(3):209–211
doi: 10.1159/000050860
pubmed: 11340393
Kucuk E, Yilmaz U, Zor KR (2020) Tear Film functions and Dry Eye symptoms in young patients with Pterygium. Beyoglu Eye J 5(1):26–31
pubmed: 35098058
pmcid: 8784441
Zhuo R et al (2019) Inferior Quadrant of tear Film is more likely to Break and Breaks early in patients with dry eyes. Cornea 38(5):624–631
doi: 10.1097/ICO.0000000000001886
pubmed: 30912769
Roka N, Shrestha SP, Joshi ND (2013) Assessment of tear secretion and tear film instability in cases with pterygium and normal subjects. Nepal J Ophthalmol 5(1):16–23
doi: 10.3126/nepjoph.v5i1.7816
pubmed: 23584641
Tsubota K (2018) Short tear Film Breakup Time-Type Dry Eye. Invest Ophthalmol Vis Sci, 59(14): p. Des64-des70.
Lan W et al (2012) Nuclear Factor-κB: central regulator in ocular surface inflammation and diseases. Ocul Surf 10(3):137–148
doi: 10.1016/j.jtos.2012.04.001
pubmed: 22814642
Bradley JC et al (2010) The science of pterygia. Br J Ophthalmol 94(7):815–820
doi: 10.1136/bjo.2008.151852
pubmed: 19515643
Di Girolamo N, Wakefield D, Coroneo MT (2006) UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci 47(6):2430–2437
doi: 10.1167/iovs.05-1130
pubmed: 16723453
Enríquez-de-Salamanca A et al (2010) Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 16:862–873
pubmed: 20508732
pmcid: 2874579
Van Acker SI et al (2019) Pterygium Pathology: A Prospective Case-Control Study on Tear Film Cytokine Levels Mediators Inflamm, 2019: p. 9416262
Li M et al (2007) Tear function and goblet cell density after pterygium excision. Eye (Lond) 21(2):224–228
doi: 10.1038/sj.eye.6702186
pubmed: 16341136
Mochizuki M, Sugita S, Kamoi K (2013) Immunological homeostasis of the eye. Prog Retin Eye Res 33:10–27
doi: 10.1016/j.preteyeres.2012.10.002
pubmed: 23108335
Goetz FW, Planas JV, MacKenzie S (2004) Tumor necrosis factors. Dev Comp Immunol 28(5):487–497
doi: 10.1016/j.dci.2003.09.008
pubmed: 15062645
Medler J, Wajant H (2019) Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. Expert Opin Ther Targets 23(4):295–307
doi: 10.1080/14728222.2019.1586886
pubmed: 30856027
Chauhan SK et al (2009) Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol 182(3):1247–1252
doi: 10.4049/jimmunol.182.3.1247
pubmed: 19155469
Bolstad AI et al (2012) Association between genetic variants in the tumour necrosis factor/lymphotoxin α/lymphotoxin β locus and primary Sjogren’s syndrome in scandinavian samples. Ann Rheum Dis 71(6):981–988
doi: 10.1136/annrheumdis-2011-200446
pubmed: 22294627
Pikor NB et al (2015) Integration of Th17- and lymphotoxin-derived signals initiates meningeal-resident stromal cell remodeling to Propagate Neuroinflammation. Immunity 43(6):1160–1173
doi: 10.1016/j.immuni.2015.11.010
pubmed: 26682987
Upadhyay V, Fu YX (2013) Lymphotoxin signalling in immune homeostasis and the control of microorganisms. Nat Rev Immunol 13(4):270–279
doi: 10.1038/nri3406
pubmed: 23524463
pmcid: 3900493
Chiang EY et al (2009) Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 15(7):766–773
doi: 10.1038/nm.1984
pubmed: 19561618
Stepp MA, Menko AS (2021) Immune responses to injury and their links to eye disease. Transl Res 236:52–71
doi: 10.1016/j.trsl.2021.05.005
pubmed: 34051364
pmcid: 8380715